Latest Treatment Strategy for Neurological Disorders
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 8744
Special Issue Editor
2. Department of Neurosciences, Università Cattolica del S. Cuore, 00168 Rome, Italy
Interests: neurogenetics; neurological diseases; neurodegeneration; clinical neurophysiology; neuromuscular disorders
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
To date, there are few effective treatments approved and available for patients with neurological disorders, and in many cases, the therapeutic options focus on the symptomatic management of disease manifestations, aiming to improve patients' quality of life.
In recent years, basic researchers and clinicians have worked together, sharing research projects and planning clinical trials, to improve this scenario, with results leading in some cases to a real therapeutic revolution, such as in spinal muscular atrophy (SMA). Important therapeutic advantages have also been achieved in other rare neurological pathologies both of genetic and autoimmune etiology, such as hereditary transthyretin amyloidosis (ATTRv) or myasthenia gravis. At the same time, innovative approaches have changed the therapeutic options for common neurological diseases, such as migraine.
Finally, an increasingly accurate metabolic–molecular characterization of hereditary and acquired neurological disorders (e.g., mitochondrial diseases, multiple sclerosis, neurodegenerative diseases of the central nervous system and movement disorders) is defining new therapeutic perspectives, sometimes unexpected.
For this Special Issue titled “Latest Treatment Strategy for Neurological Disorders”, we are looking for original research articles and state-of-the-art reviews on preclinical and clinical therapeutic approaches, both in common and rare neurological diseases, focused on a molecular point of view.
Dr. Guido Primiano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- personalized medicine
- neurological disorders
- neurogenetic diseases
- mitochondrial diseases
- spinal muscular atrophy
- neurodegenerative diseases
- autoimmune disease
- treatment
- therapeutics
- biological mechanisms
